ArticleCell biochemistry and biophysics2025
DCAF13 Regulates Cell Proliferation and Immune Escape of Hepatocellular Carcinoma Through Activating the NF-κB Pathway.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- NF-κB signaling in hepatocellular carcinoma: Mechanisms of tumor progression, immune evasion, and therapeutic resistance.Translational oncology · 2026Review
- Unveiling the Intricate Dance: Signaling Pathways in Liver Cancer Metabolism and Immunity.Current oncology reports · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC), the third leading cause of global cancer deaths, has a high unmet clinical need due to limited therapeutic efficacy. Immune escape mechanisms in the tumor microenvironment further complicate treatment. Advances in bioinformatics and machine learning offer potential for identifying novel biomarkers and therapeutic targets. This study aimed to identify immune-related prognostic biomarkers for HCC using integrative bioinformatics and machine learning, and validate their functional roles in tumor progression and immune escape. mRNA data from TCGA and GEO databases were analyzed to identify differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) and three machine learning models (Random Forest, Boruta, XGBoost) were applied to screen key genes. Candidate genes were validated using qRT-PCR, Western blot, and functional assays (CCK8, colony formation, LDH, flow cytometry) in HCC tissues and cell lines. Immune correlations were assessed via CIBERSORT, and TNF-α/NF-κB pathway involvement was investigated. Total 26 genes were screened as HCC biomarkers through machine learning analysis. DCAF13 emerging as an independent prognostic factor. It was overexpressed in HCC tissues and cells, correlating with poor survival. Sh-DCAF13 suppressed proliferation, reduced PD-L1 expression, enhanced CD8 + T cell cytotoxicity, and decreased T cell apoptosis, inhibiting immune escape. TNF-α overexpression reversed these effects by restoring NF-κB activation. DCAF13 is a promising therapeutic target for HCC. Its role in modulating immune escape via the NF-κB pathway highlights potential strategies for personalized immunotherapy. Integrating machine learning with experimental validation provides a robust framework for biomarker discovery in oncology.
Indexed as
Identifiers
40603761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.